We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Thai pharmaceutical companies were told by the Food and Drug Administration
(FDA) to develop their products in order to meet international quality standards
in a bid to boost the nation's competitiveness in the international pharmaceuticals
market.
Chugai Pharmaceutical announced on April 4 that it has decided to halt the development
of R212, a drug candidate for the treatment of obesity, in Japan.
WEX Pharmaceuticals is pleased to announce that it has received a EUR 2,000,000
payment from its co-development partner, Laboratorios del Dr. Esteve S.A.
Biopharmaceutical firm Indevus Pharmaceuticals has been
granted GBP26 million in funding from the UK government and the UK's Medical
Research Council for a phase III clinical trial of PRO 2000, an HIV prevention
product.
With the issues of patent protection and international co-operation
already severe causes of friction between the Israeli government and the multinational
drugmakers, pricing structures have also attracted heavy criticism in recent
years.
Sales of ethical erectile dysfunction (ED) therapies have soared
in Brazil in recent years, far outpacing even the optimistic forecasts of multinational
drugmakers.
AEterna Zentaris today announced that its subsidiary, Atrium Biotechnologies,
has successfully completed its initial public offering and secondary offering
of 6,250,000 subordinate voting shares, issued at a price of $12 per share,
for total proceeds of $75 million.